Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

Start Date12 Nov 2024

Sponsor / Collaborator-

NCT06443255

/ CompletedPhase 3IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

Start Date01 Jul 2024

Sponsor / Collaborator

Rigshospitalet

NCT05809453

/ CompletedPhase 1/2IIT

Intranasal Cocaine and Temperature Regulation During Exercise

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

Start Date01 Sep 2023

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Cocaine Hydrochloride

100 Translational Medicine associated with Cocaine Hydrochloride

100 Patents (Medical) associated with Cocaine Hydrochloride

49,570

Literatures (Medical) associated with Cocaine Hydrochloride

01 Oct 2025·Medicina de Familia-SEMERGEN

Tentativa de suicidio: evolución de las visitas en Urgencias de un hospital comarcal en Barcelona, estudio transversal de 2019 a 2023

Article

Author: Guil Sànchez, J

OBJECTIVE:

To study the characteristics of patients who consulted in the emergency department for suicide attempts between 2019-2023 and the characteristics of the episodes.

MATERIAL AND METHODS:

Descriptive study from 1 January 2019 to 31 December 2023. We included demographic variables (sex, age), clinical variables (psychiatric history, psychotropic medication, substance abuse, follow-up in Mental Health, existence of previous self-harm attempt) and characteristics of the episode (mechanism, motive, destination).

RESULTS:

810 patients consulted, 64.6% women, mean age 39.6±18.1. They had a psychiatric history 688 (84.9%): men 228 (79.4%), women 460 (87.9%). Follow-up in Mental Health 384(47,4%): men 115 (40,1%), women 269 (51,4%). They had a previous suicide attempt 271 (33.5%): men 78 (27.2%), women 193 (36.9%). They used intoxicants 226(32.8%): men 131 (45.6%), women 135 (25.8%), alcohol 197 (87.2%), cocaine 115 (43.2%), and THC 108 (40.6%). In 551 (68%) episodes the mechanism was drug intake. Benzodiazepines came first, 423 (76.8%), followed by antidepressants 119 (21.2%) and analgesic/NSAIDs 89 (16.1%). Ingestion of intoxicants was 185 (22.8%), 82 (28.6%) men, 103 (19.7%) women, alcohol in 148 (80%). Self-inflicted injuries were present in 88 (10.9%). There were 331 (40.9%) cases with triggers: relationship problems 115 (34.7%), family problems 106 (32%). 608(75.1%) patients were referred to Mental Health, 73(9%) were admitted to Psychiatric Units.

CONCLUSIONS:

Consulted 810 patients between 2019-2023, an 80.8% increase in ED consultations for suicide attempts during the study period. The majority were women and had a psychiatric history. Approximately half were being followed up in Mental Health. One third had previously attempted suicide. Most were due to medication intake, mainly benzodiazepines. The main triggers were relationship and family problems. 75.1% of patients were referred to Mental Health, 9% were admitted to Psychiatric Units.

01 Oct 2025·ADDICTIVE BEHAVIORS

Article

Author: Efrati, Yaniv

While significant progress has been made in understanding the prevalence of use and severity of addictive behaviors, there remains a lack of research adopting a lay epidemiological approach to examine a broad spectrum of addictive behaviors among a large youth population. The objective of this study is to investigate the frequencies of use and severity of various addictive-like behaviors across different demographic variables including gender, religion, country of birth, religiosity, socio-economic status, and age. The sample comprised 6,849 Jewish and Arabic Israeli youth from the general community, consisting of 2,776 males (41 %) and 4,074 females (59 %), 12-18 years of age (M = 15.92, SD = 1.27) who completed the survey anonymously and with parental consent. Results indicated that higher severity in one addictive behavior correlates with increased severity in others. Substance-related behaviors such as alcohol, tobacco, cannabis, and cocaine showed stronger correlations within their group than with behavioral addictions like gambling, shopping, gaming, eating disorders, sexual activity and social networking. Similarly, behavioral addictions also display stronger correlations within their own cluster. In addition, significant prevalence of use and severity differences were observed in addictive behaviors based on gender, religion, country of birth, religiosity, socio-economic status, and age. The research underscores the critical role of providing support and resources to youth, which is essential for preventing addictive behaviors and reducing the risks associated with their development.

01 Oct 2025·TALANTA

Article

Author: Calero-Cañuelo, Carlos ; Cárdenas, Soledad ; Lucena, Rafael

Direct analysis by mass spectrometry (MS) has emerged as a promising strategy for analyzing a broad range of samples. Among the different ionization techniques, plasma-based sources are simple alternatives that can be used to ionize a wide range of analytes, thus providing high analytical versatility. This article describes the design of a simple and cost-effective interface that uses adhesive tapes as both sampling probes and thermal desorption substrates. The particulate solid sample is adhered to the tape in a single and quick step, avoiding particle losses and protecting the interface from clogging. The probe is thermally desorbed in a dedicated chamber, built using commercial elements, in front of the MS inlet. The desorbed analytes are driven by the vacuum system (any supplementary carrier gas is not required), passing through the plasma-based source (Soft Ionization by Chemical Reaction In Transfer, SICRIT®), where they are ionized before being introduced in the spectrometer. The determination of caffeine in coffee has been evaluated as a proof of concept since the complexity of the matrix and the semivolatile character of the analyte can challenge the performance, allowing to check the potential of the new approach. The type of adhesive tape, the parameters related to the desorption and sample dilution have been studied in depth. Working under optimum conditions, LOD was settled down at 0.18 mg g^-1. The intra-day and inter-day precision, expressed as relative standard deviation and calculated at three different concentration levels, were better than 12.5 and 13.7 %, respectively. Finally, the accuracy of this method was calculated by analyzing five different coffee samples and comparing the results with those provided by a reference method. The accuracy was in the range of 82.3-105.5 %. This interface is presented as a promising, simple, solvent-free approach for the direct analysis of solid samples. The interface has been finally applied to the analysis of drug mixtures to demonstrate its versatility.

230

News (Medical) associated with Cocaine Hydrochloride

17 Jun 2025

·www.filament.health

Filament Health Enters Into Exclusive License Agreement With University Of Alabama at Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder

The data supports Filament’s PEX010 drug development program targeting stimulant use disorders PEX010 is a first-in-class botanical psilocybin drug candidate currently under investigation in 52 clinical trials worldwide for 14 mental health indications Vancouver, British Columbia, June 17, 2025 – Filament Health Corp. (OTC:FLHLF) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced that it has entered into an exclusive global license agreement with the University of Alabama at Birmingham (UAB) for intellectual property related to a recently completed Phase 2 placebo-controlled clinical trial of psilocybin as a treatment for cocaine use disorder (CUD). The study investigated the safety and efficacy of a single-dose of psilocybin compared to placebo comparator in 40 adult patients with severe CUD. The trial was led by Principal Investigator Peter Hendricks, Ph.D., University Professor and Heersink Endowed Chair of Psychiatry at the UAB Department of Psychiatry and Behavioral Neurobiology, and a globally recognized expert in psychedelic-assisted therapies for addiction. “The results of the study demonstrated that psilocybin was well-tolerated and that a single dose resulted in a significant and durable reduction in cocaine use among people with CUD who were representative of cocaine users from the Deep South region of the United States. This is notable as most psychedelic trials fail to recruit participants representative of the population of those who could benefit from care.,” said Dr. Hendricks. “We expect to have our data published in a peer-reviewed journal later this year and are excited to contribute to the science and possibly help bring to the clinic a promising treatment for cocaine and other stimulant use disorders in the future.” Filament has obtained rights to access and use the data, know-how, and associated intellectual property from the clinical study, in furtherance of the Company’s own proprietary development programs in stimulant use disorders. The partnership will also enable Dr. Hendricks to serve as an advisor to Filament Health and to advance research into other substance use conditions. “This agreement marks an important step in our mission to advance PEX010 and our other programs for the treatment of patients with stimulant use disorders,” said Benjamin Lightburn, Co-Founder and Chief Executive Officer of Filament. “We are a leading developer of psychedelic drug candidates for substance use disorders and other mental health conditions. The positive data from Dr. Hendricks’ trial, as well as his knowledge of clinical practices and ongoing counsel, will be significant assets in facilitating the advancement of our research.” Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at www.filament.health and on Twitter, Instagram, and LinkedIn. media@filament.health ir@filament.health Certain statements and information contained in this press release and the documents referred to herein may constitute “forward‐looking statements” and “forward‐looking information,” respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. ‍

Phase 2License out/in

11 Jun 2025

·www.globenewswire.com

Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing

SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an update on its growing footprint in the U.S. Forensic Use Only Market through its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services. SMARTOX supports clients across corrections, drug courts, rehabilitation centres, and other forensic environments. It has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone, highlighting accelerated demand for non-invasive, rapid testing in forensic settings. INBS' drug screening technology is credited with reducing reliance on invasive methods such as urine or saliva collection, while delivering rapid and reliable results directly linked to the individual tested. As adoption grows in the U.S. Forensic Use Only market, INBS continues to actively pursue FDA clearance for its opiate test system for codeine. This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology. "We have partnered with SMARTOX to expand access to our fingerprint drug screening system across key forensic settings such as criminal justice," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "SMARTOX's commitment to innovation aligns with our mission to transform drug testing through intelligent, non-invasive technologies." SMARTOX is known for its expertise, innovation, and customer-focused approach to drug testing. Its portfolio includes DOT compliance solutions, instant and lab-based testing, and advanced technologies, including INBS' Intelligent Fingerprinting Drug Screening System, which enables hygienic, non-invasive drug screening in under ten minutes using fingerprint sweat. In addition to serving clients across the U.S., SMARTOX reaches international markets through its distribution network, including Europe, Latin America, New Zealand, and Australia. "Our clients consistently report that the Intelligent Fingerprinting Drug Screening System improves efficiency, enhances user dignity, and simplifies operations," said Duffy Nabors, Vice President of Sales and Marketing at SMARTOX. "They value its speed, ease of use, and non-invasiveness, along with the ability to eliminate gender-specific staff requirements and special facilities. These benefits help our clients reduce turnaround times, lower costs, and eliminate logistical complexities, improving the overall testing experience." About SMARTOX SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services. It offers a comprehensive portfolio supporting a wide range of settings, including healthcare, justice, corporate, and education. SMARTOX is committed to delivering advanced technology and exceptional results, providing fully integrated services encompassing design, customer service, and administrative support for its product line. The company's footprint spans the U.S. and international markets. SMARTOX is actively scaling its presence in forensic testing markets through new investments, pilot programs, and expanded jurisdictional coverage. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit: https://www.ibs.inc Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:   Intelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter Investor & Media Contact:  Valter Pinto, Managing Director  KCSA Strategic Communications  PH: (212) 896-1254  INBS@kcsa.com

05 Jun 2025

·pharma.economictimes.indiatimes.com

Surge in new opioids and designer drugs threatens Europe, EU drug agency warns

Madrid: Massive shipments of previously unknown recreational designer drugs and potent new opioids are threatening Europe, while traffic of cocaine and cannabis is worsening, according to the European Union Drugs Agency's annual report published on Thursday. Seizures of synthetic cathinones - stimulants chemically akin to the active ingredient in khat, a plant widely consumed in East Africa and the Arabian Peninsula - reached 37 metric tons in 2023, primarily imported from India. Seven new cathinones were identified last year, suggesting their growing prevalence. The report also warned of new synthetic opioids, particularly nitazenes, which it said posed "severe poisoning" risks. Nitazenes can be orders of magnitude stronger than heroin - or even fentanyl - and have been linked by U.S. and British authorities to increases in overdose deaths. The report - which compiled data from the 27 EU member states plus Norway and Turkey - stressed the need for improved monitoring and alert systems, as well as better preparedness and cross-sector collaboration to combat drug-related crime and public health risks. Meanwhile, cannabis remained Europe's most consumed illicit drug, with increasingly potent products complicating health risk assessments. The average tetrahydrocannabinol (THC) content in cannabis resin has doubled over the past decade, the report said. In 2024, authorities detected 18 new varieties of semi-synthetic cannabinoids such as hexahydrocannabinol (HHC), which in many countries can be sold legally because those molecules are often not explicitly banned. Cocaine use was also rising, as shown by record seizures of 419 tons in 2023. Major ports in Belgium, Spain, and the Netherlands were key entry points, the report said. (Reporting by David Latona; Editing by Inti Landauro and Edwina Gibbs)

100 Deals associated with Cocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02182	Cocaine Hydrochloride	S01HA01 S02DA02 N01BC01	DB00907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	Noden Pharma DAC	14 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	United States	Biotie Therapies Oy	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2024	Not Applicable	Compartment Syndromes \| Hyperkalemia	-	Cocaine	mojoxrzpxl(axynvlhlih) = showed a Wellens' pattern with ST-elevation and biphasic T-waves in lead V2-V3 mwtcuwxeea (jvterzptog ) View more	-	19 May 2024
P2-4.012 (AAN2024)	Not Applicable	Ischemic stroke	-	Cocaine users	blahdrkgzk(siafuxpxdr) = awrpqqbcyt tdjigipzdf (uvlmnmrzzr )	Negative	09 Apr 2024
				Non-cocaine users	blahdrkgzk(siafuxpxdr) = lddicforhg tdjigipzdf (uvlmnmrzzr )
SAT439 (ENDO2023)	Not Applicable	Diabetic Ketoacidosis	-	Empagliflozin 25mg daily	svqdjygyee(pnvualwpyd) = Due to patients’ severe acidosis and concerns for cardiac arrest, he was intubated for airway protection and admitted to the ICU for further management. DKA protocol was initiated and treatment with IV insulin, IV 5% Dextrose, 0.45% normal saline, potassium replacement, and IV bicarbonate provided until anion gap closed and acidosis resolved. Eventually, patient was successfully extubated and transferred to ward for further management and diabetic treatment optimization. rnhxcfwgnp (rtblfaxvbu ) View more	Positive	05 Oct 2023
ATS2023	Not Applicable	Complication	-	Cocaine inhalation	ueqwwkkvkb(lbyslvyirl) = Prevention of pulmonary toxicity requires cessation of cocaine use and a referral to a substance use treatment program is advised. oplppcjhkm (lepdpqetat ) View more	-	21 May 2023
ATS2023	Not Applicable	Bronchiolitis	-	Cocaine	ovgjiuvvvj(tmiwanlklf) = otmwilnaws lmzytnixmv (ktipahpxvq ) View more	-	21 May 2023
NCT02537873 (CTgov)	Phase 1	Cocaine-Related Disorders	29	Cocaine+Lorcaserin (Arm 1: Lorcaserin and Cocaine IV)	vcytilerhe(pwwsxjbnpr) = vdztrzilje dpwaedmzme (koceadbroo, 7.98) View more	-	12 May 2020
				Cocaine+Placebo comparator (Arm 2: Placebo Comparator and Cocaine IV)	vcytilerhe(pwwsxjbnpr) = kanqeaocsk dpwaedmzme (koceadbroo, 6.94) View more
NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	hxmnqqdpss(zskwjcvbgo) = ykunavsndl kpzaootbve (uwmdkajisy, 1.39) View more	-	17 May 2019
				Placebo+Cocaine (Medium Value Reinforcer)	hxmnqqdpss(zskwjcvbgo) = wpjzizmvkr kpzaootbve (uwmdkajisy, 0.53) View more
NCT02383043 (CTgov)	Early Phase 1	Cocaine-Related Disorders	18	Cocaine+Sustained Release d-Amphetamine	kzfcmscdje(fytkhgphgd) = tlnlwaebed tbbgjotfgo (kaielrmlfw, 0.35) View more	-	11 Apr 2019
AAN2018	Not Applicable	Acute Ischemic Stroke cocaine use	-	AIS with cocaine use	mloitcfmgf(behnzxtzbr) = scsbcatidw cpgnckknec (krxkpfhhjg ) View more	-	10 Apr 2018
				AIS without cocaine use	mloitcfmgf(behnzxtzbr) = bmauudvjzo cpgnckknec (krxkpfhhjg ) View more
ACR2017	Not Applicable	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ANCA antibodies \| inflammatory markers \| haematology and biochemistry profiles	14	Cocaine-induced vasculitis	lgjczjgckh(bqrnourkkq) = flfjphyitb rsyelcphqc (jvutxidqjk ) View more	Negative	06 Nov 2017
				Cocaine (Idiopathic ANCA vasculitis)	lgjczjgckh(bqrnourkkq) = sezswqrmnh rsyelcphqc (jvutxidqjk )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis